Revlimid boosts survival in myeloma patients post-transplant

Celgene has unveiled a meta-analysis of pooled data from three late-stage studies showing a significant overall survival (OS) benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation (ASCT). The meta-analysis pooled data from 1,208 patients newly diagnosed in multiple myeloma who underwent ASCT in three randomised, controlled Phase III studies (CALGB 100104, IFM 2005-02, GIMEMA RVMM-PI-209). The findings, published as a Rapid Communication in the Journal of Clinical Oncology, show that Revlimid (lenalidomide) maintenance therapy cut the risk of death by 25 percent versus placebo/observation.